How BPC-157 works: the blood-supply trick behind the repair

Cut the blood supply to a patch of tissue and it more or less stops healing. That’s not a figure of speech. It’s the reason a torn tendon can nag for a whole season while a split lip closes in days — tendons get almost no blood, and lips are soaked in it. Nearly every BPC-157 claim you’ve read traces back to that one fact.

Strip away the long list of things the peptide is supposed to fix and a single idea sits underneath all of it. BPC-157 appears to build fresh blood supply straight into damaged tissue. One move. That’s the mechanism worth understanding, because if it’s real, it explains the whole reputation — and we walk the full range of what it’s claimed to do in the BPC-157 overview.

What that one move could do for you

Picture the injuries that drag. A cranky Achilles. A shoulder that won’t settle. A hamstring that keeps pulling. They all take forever for the same underlying reason: not enough blood reaching the damage. Less blood means less oxygen and fewer repair cells getting to where the work is.

Now hand the body a signal that lays down new plumbing right into that tissue. More vessels, more supply, more of the repair crew arriving on site. In animal models, that’s exactly BPC-157’s signature move — and it’s the likely reason rat tendons bounce back faster than they should.

Here’s what lifts it above a one-trick compound. Almost every injury runs on that same need for blood. So a signal that improves the supply line plausibly helps in a lot of places at once — a stiff tendon, a torn muscle, an irritated gut lining — instead of just one. That breadth is the whole appeal. If the animal signal carries into people, it’s one of the more useful things a recovering body could reach for.

The two pathways it runs on

The mechanism comes down to two things, and both are easy to picture.

The first is angiogenesis — the growth of new blood vessels. When you damage tissue, your body normally sprouts tiny new vessels to feed the repair. BPC-157, in animal work, appears to push that process harder and faster. A 2025 review in Pharmaceuticals by Józwiak and colleagues catalogues those angiogenic effects across decades of animal studies.

The second is nitric oxide — a short-lived signal your body uses to relax blood vessels and keep blood moving. Picture angiogenesis as building new roads and nitric oxide as keeping the traffic flowing on them. BPC-157’s original research group, led by Predrag Sikirić in Zagreb, argues in a 2025 comment that the peptide works mainly through this pathway — and that because the nitric-oxide signal turns up in nearly every tissue, one compound can reach so many of them.

Roads plus traffic, with everything else downstream. That’s the cleanest version of the mechanism the science has. It’s a hypothesis with a lot of animal evidence behind it, not a settled fact.

How far the mechanism is actually proven

Now the part that keeps this honest. Almost all of it comes from rats.

The animal evidence is real, and it’s consistent. Consistent enough that a 2025 systematic review in HSS Journal calls BPC-157 an emerging candidate in orthopaedic sports medicine, and a 2026 review extends the same mechanism to the tendon-to-bone junctions that heal slowest. But a rat is not you. Nobody has shown the angiogenesis-and-nitric-oxide story runs the same way in a person, and most of the animal work traces back to that one Zagreb lab — which isn’t the same as a dozen independent groups landing on the same answer.

There’s one open question worth naming straight, because it cuts both ways. The same new-vessel growth that could speed your repair is the process a tumour uses to feed itself. Józwiak’s review raised whether the mechanism could carry a cancer-relevant risk. Sikirić’s group answered that decades of animal data point to protection of healthy cells, not tumour growth. Both reads are defensible. Nobody has settled it in humans. Does BPC-157 feed cancer? Honestly, nobody knows — no study has confirmed it, and none has ruled it out.

Where the FDA review sits

BPC-157 is the headline name on the FDA’s summer review. It’s among the bulk drug substances on the Pharmacy Compounding Advisory Committee’s July 23, 2026 docket per Federal Register notice 2026-07361, and the use the FDA listed for review is ulcerative colitis — a gut-lining indication, not the tendon repair most of its buyers are chasing.

Sit with that mismatch for a second. The compound goes in front of the committee for the gut-mucosa job that matches where it was first found, in gastric juice. The tendon-repair use driving demand isn’t the one on the table. What a PCAC review actually decides is a longer story, told in what a PCAC review actually is. The short version: it’s an advisory committee weighing whether the compound belongs on a list. That’s not an approval.

One thing a vote won’t change: BPC-157 sits on the WADA prohibited list, banned in and out of competition. If you’re drug-tested, treat it as off-limits and check the current code on the day.

Where the mechanism goes from here

Here’s the genuinely hopeful part, and it’s new. For the first time, the right experiment is running. A Phase 2 placebo-controlled trial in people with hamstring strains (NCT07437547) started recruiting in 2026 — the first controlled human test of BPC-157 in an actual injury. It hasn’t reported yet. But after thirty years of rat work, the mechanism is finally being checked in people. We track the thin human file in more depth in the injury-recovery deep-dive.

Add it up and BPC-157 sits in a rare spot — a clean, plausible mechanism, a mountain of animal evidence, and an almost empty human file. The idea is exciting. The proof isn’t finished. Neither of those cancels the other.

The honest way to reach for something this promising isn’t a powder off a research-chemical site, dosed off a rat and assayed by nobody. It’s a US-licensed pharmacy compounding it, a physician putting their name on the prescription, and every batch tested before it goes anywhere near you. That’s what Wolverine Health is being built to be. It can’t open until the regulation does, and that July session is the first domino. Leave your email and we’ll tell you the day the mechanism stops being a rat story and becomes something you can actually get.